Book contents
- Rare Causes of Stroke
- Rare Causes of Stroke
- Copyright page
- Contents
- Contributors
- Preface
- 1 Inflammatory Conditions
- 2 Infectious and Postinfectious Vasculitis
- 3 Hypercoagulable Causes of Stroke
- 4 Drug-Related Stroke
- 5 Hereditary and Genetic Causes of Stroke
- 6 Rare Causes of Cardioembolism
- 7 Vasospastic Conditions and Other Vasculopathies
- 8 Other Non-inflammatory Vasculopathies
- 9 Venous Occlusive Conditions
- 10 Bone Disorders and Stroke
- Index
- References
3 - Hypercoagulable Causes of Stroke
Published online by Cambridge University Press: 06 October 2022
Edited by
Book contents
- Rare Causes of Stroke
- Rare Causes of Stroke
- Copyright page
- Contents
- Contributors
- Preface
- 1 Inflammatory Conditions
- 2 Infectious and Postinfectious Vasculitis
- 3 Hypercoagulable Causes of Stroke
- 4 Drug-Related Stroke
- 5 Hereditary and Genetic Causes of Stroke
- 6 Rare Causes of Cardioembolism
- 7 Vasospastic Conditions and Other Vasculopathies
- 8 Other Non-inflammatory Vasculopathies
- 9 Venous Occlusive Conditions
- 10 Bone Disorders and Stroke
- Index
- References
- Type
- Chapter
- Information
- Rare Causes of StrokeA Handbook, pp. 151 - 184Publisher: Cambridge University PressPrint publication year: 2022
References
References
Linnemann, B. Antiphospholipid syndrome: An update. Vasa. 2018;47(6): 451–464.CrossRefGoogle ScholarPubMed
Ricarte, IF, Dutra, LA, Abrantes, FF, et al. Neurologic manifestations of antiphospholipid syndrome. Lupus. 2018;27(9): 1404–1414.CrossRefGoogle ScholarPubMed
Fleetwood, T, Cantello, R, Comi, C. Antiphospholipid syndrome and the neurologist: from pathogenesis to therapy. Front Neurol. 2018;9: 1001.CrossRefGoogle ScholarPubMed
Miyakis, S, Lockshin, MD, Atsumi, T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2): 295–306.CrossRefGoogle Scholar
Cervera, R, Piette, JC, Font, J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4): 1019–1027.CrossRefGoogle Scholar
References
Welch, GN, Loscalzo, J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338: 1042–1050.CrossRefGoogle ScholarPubMed
Selhub, J, Jaques, PF, Bostom, AG, et al, Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332: 286–291.CrossRefGoogle ScholarPubMed
Clarke, R, Daly, L, Robinson, K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324: 1149–1155.CrossRefGoogle ScholarPubMed
Den Heijer, M, Kostor, T, Blom, HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334: 759–762.CrossRefGoogle ScholarPubMed
Quin, X, Li, J, Spence, JD, et al. Folic acid therapy reduces the first stroke risk associated with hypercholesterolemia among hypertensive patients. Stroke. 2016;47: 2805–2812.CrossRefGoogle Scholar
Ahmed, S, Bogiatzi, C, Hackam, DG, et al. Vitamin B12 deficiency and hyperhomocysteinaemia in outpatients with stroke or transient ischaemic attack: A cohort study at an academic medical centre. BMJ Open. 2019;9: e026564.CrossRefGoogle ScholarPubMed
American Heart Association Stroke CouncilPowers, WJ, Rabinstein, AA, Ackerson, T et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018;49: e46–e110.CrossRefGoogle ScholarPubMed
References
Dashe, JF. Hyperviscosity and strokes. In: Caplan, LR, Biller, J (Eds). Uncommon Causes of Stroke. Cambridge: Cambridge University Press; 2018. 408–417.CrossRefGoogle Scholar
Perez Rogers, A, Estes, M. Hyperviscosity Syndrome. [Updated 2020 Apr 27]. Treasure Island (FL): StatPearls Publishing; 2020. www.ncbi.nlm.nih.gov/books/NBK518963/ (accessed February 2022).Google Scholar
Gertz, MA. Acute hyperviscosity: Syndromes and management. Blood. 2018;132(13): 1379–1385.CrossRefGoogle ScholarPubMed
Weaver, A, Rubinstein, S, Cornell, RF. Hyperviscosity syndrome in paraprotein secreting conditions including Waldenstrom macroglobulinemia. Front Oncol. 2020;10: 815.CrossRefGoogle ScholarPubMed
Talahma, M, Strbian, D, Sundararajan, S. Sickle cell disease and stroke. Stroke. 2014;45(6): e98–e100.CrossRefGoogle ScholarPubMed
References
Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH), Taylor, FB Jr, Toh, CH, Hoots, WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. ThrombHaemost. 2001;86: 1327–1330.Google Scholar
Wada, H, Matsumoto, T, Yamashita, Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. 2014;2(1): 15.CrossRefGoogle ScholarPubMed
Sarode, R, Bandarenko, N, Brecher, ME, et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher. 2014;29(3): 148–167.CrossRefGoogle ScholarPubMed
Moncayo-Gaete, J, Correa, P. Thrombotic thrombocytopenic purpura. In: Caplan, LR, Biller, J (Eds). Uncommon Causes of Stroke. Cambridge: Cambridge University Press; 2018. 347–355.CrossRefGoogle Scholar
Amorosi, E, Ultmann, J. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore). 1966;45: 139–159.CrossRefGoogle Scholar
Rojas, JC, Banerjee, C, Siddiqui, F, Nourbakhsh, B, Powell, CM. Pearls and oy-sters: acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura. Neurology. 2013;80(22): e235–e238.CrossRefGoogle ScholarPubMed
Matsumoto, M, Fujimura, Y, Wada, H, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol. 2017;106(1): 3–15.CrossRefGoogle ScholarPubMed
References
Sokol, DK, McIntre, JA, Short, RA, et al. Henoch-Schonlein purpura and stroke: Antiphosphatidylethanolamine antibody in CSF and serum. Neurology. 2000;55: 1379.CrossRefGoogle ScholarPubMed
Garzoni, L, Vanoni, F, Rizzi, M, et al. Nervous system dysfunction in Henoch-Schonlein syndrome: Systematic review of the literature. Rheumatology. 2009;48: 524–529.CrossRefGoogle ScholarPubMed
Oni, L, Sampath, S. Childhood IgA vasculitis (Henoch Schonlein Purpura): Advances and knowledge gaps. Front Pediatr. 2019;27(7): 257.CrossRefGoogle Scholar
González-Gay, MA, López-Mejías, R, Pina, T, et al. IgA vasculitis: Genetics and clinical and therapeutic management. Curr Rheumatol Rep. 2018;20: 24.CrossRefGoogle ScholarPubMed
References
Sanossia, N, Djabiras, C, Mack, WJ, Ovbiagele, B. Trends in cancer diagnoses among inpatients hospitalized with stroke. J Stroke Cerebrovasc Dis.2013,22:1146–1150).CrossRefGoogle Scholar
Navi, BB, Reiner, AS, Kamel, H, et al. Association between incident cancer and subsequent stroke. Ann Neurol. 2015;77: 291–300.CrossRefGoogle ScholarPubMed
Navi, BB, Singer, S, Merkler, AE, et al. Recurrent thromboembolic events after ischemic stroke. Neurology. 2014;83: 26–33.CrossRefGoogle ScholarPubMed
Nam, KW, Kim, CK, Kim, TJ, et al. D-dimer as a predictor of early neurological deterioration in cryptogenic stroke with active cancer. Eur J Neurol. 2017;24: 205–211.CrossRefGoogle ScholarPubMed
Bang, OY, Seok, JM, Kim, SG, et al. Ischemic stroke and cancer: Stroke severely impacts cancer patients, while cancer increase the numbers of strokes. J Clin Neurol. 2011;7: 53–59.CrossRefGoogle ScholarPubMed
Raskob, GE, van Es, M, Verhamme, P, et al. Edoxaban for the treatment of cancer -associated venous thromboembolism. New Engl J Med. 2018;378: 615–624.CrossRefGoogle ScholarPubMed